A switch may be considered because of side effects, response, access, or a change in your health. It is a new prescribing decision. A dose number from one product is not an equivalent dose of another, and a product containing the same ingredient may have a different approved use, formulation, or device.
What to do next
- State the reason for switching. Bring what has improved, what has not, and what is making treatment difficult. Include how long you used each dose and whether access interruptions affected the result. This helps the clinician decide whether a switch addresses the actual problem.
- Confirm the indication and exact product. Ask whether the proposed medicine is FDA-approved for weight management and appropriate for your circumstances. YourMD's GLP-1 weight-management approach uses FDA-approved products from Novo Nordisk or Eli Lilly, rather than compounded or investigational GLP-1 products.
- Bring your last dose and device information. Include the brand, formulation, strength, schedule, date taken, and any missed doses. Ask for a written stop date and start date. There is no universal milligram conversion or do-it-yourself overlap schedule between Wegovy and Zepbound.
- Review safety before the first new dose. Discuss prior severe reactions, pancreatitis or gallbladder problems, kidney issues, severe digestive symptoms, and personal or family history of medullary thyroid cancer or MEN2. Include other diabetes medicines and every supplement on your medication list.
- Ask about pregnancy and contraception. Product instructions differ. In particular, Zepbound has additional precautions for oral hormonal contraceptives after starting and increasing the dose. Tell the prescriber about pregnancy plans before the transition, not after receiving the prescription.
- Arrange a follow-up and pharmacy check. Confirm which prescription replaces the old one, how the new device works, what to do during a delay, and when symptoms should trigger a call. Wegovy and Zepbound labeling advises against use with other GLP-1 receptor agonists; do not combine them.
When to contact your care team
Do not start a replacement while you have unexplained severe symptoms from the current treatment. Severe persistent abdominal pain, repeated vomiting, dehydration, or an allergic reaction requires prompt assessment. If the prescription and pharmacy label differ from your written plan, clarify before taking the dose.
Put it into practice
Use one message containing the current product, last dose date, reason for switching, and other medicines. Ask the care team to reply with the replacement product, start instructions, old prescription to discontinue, and follow-up date. Read those instructions back in your own words.
Notes for your next visit
Write these in your own notes or on a printed copy. Bring them to your follow-up.
- Why I am considering a switch:
- Current product and last dose; new written start instructions:
- My pharmacy question and follow-up date:
Sources and further reading
- Novo Nordisk: Wegovy prescribing information, limitations of use and safety
- Eli Lilly: Zepbound prescribing information, limitations of use and safety
Medical disclaimer: General education for adults. Follow your clinician’s individual plan and the current instructions for your prescribed product. If instructions conflict, ask your clinician or pharmacist to clarify. For a medical emergency, call 911.
https://telehealth.yourmd.online/blog/switching-weight-management-medicines-checklist